Urushiyama Miki, Tarasawa Kunio, Moroi Rintaro, Iwaki Hideya, Hoshi Yusuke, Nagai Hiroshi, Shimoyama Yusuke, Naito Takeo, Kakuta Fumihiko, Shiga Hisashi, Hamada Shin, Kakuta Yoichi, Fushimi Kiyohide, Kinouchi Yoshitaka, Abukawa Daiki, Fujimori Kenji, Masamune Atsushi
Division of Gastroenterology Tohoku University Hospital Sendai Japan.
Department of Health Administration and Policy Tohoku University Graduate School of Medicine Sendai Japan.
JGH Open. 2025 May 14;9(5):e70175. doi: 10.1002/jgh3.70175. eCollection 2025 May.
This study aimed to investigate the trends in pediatric inflammatory bowel diseases (IBD) management in Japan over the past decade.
We retrospectively analyzed data from Japan's nationwide database from 2012 to 2022. Patients aged ≤ 15 years diagnosed with Crohn's disease (CD) or ulcerative colitis (UC) were included. Trends in the use of biologics, capsule endoscopy, total parenteral nutrition (TPN), elemental diets, surgery, and granulocyte and monocyte apheresis (GMA) were examined using the Cochrane-Armitage and Jonckheere-Terpstra trend tests.
Among the 8037 and 6153 pediatric UC and CD admissions, respectively, the use of biologics increased significantly (CD: from 46.0% to 53.6%; UC: from 15.0% to 33.0%, < 0.0001). The use of capsule endoscopy in pediatric patients with CD increased markedly from 6.6% to 16.7% ( < 0.0001), whereas TPN use decreased from 8.4% to 3.0% ( < 0.0001). Surgery rates for patients with CD remained at approximately 5%, whereas those for patients with UC decreased (from 3.7% to 1.7%, = 0.002). Elemental diets for pediatric patients with CD increased (from 54.4% to 66.2%, < 0.0001). The use of GMA decreased significantly in patients with UC (from 12.1% to 2.7%, < 0.0001).
The use of biologics and capsule endoscopy has increased in pediatric patients with IBD, whereas the use of more invasive treatments has decreased. These trends suggest a shift toward less invasive and more targeted therapeutic strategies in managing pediatric patients with IBD in Japan.
本研究旨在调查过去十年日本儿童炎症性肠病(IBD)管理的趋势。
我们回顾性分析了2012年至2022年日本全国数据库中的数据。纳入年龄≤15岁诊断为克罗恩病(CD)或溃疡性结肠炎(UC)的患者。使用Cochrane-Armitage和Jonckheere-Terpstra趋势检验来研究生物制剂、胶囊内镜、全胃肠外营养(TPN)、要素饮食、手术以及粒细胞和单核细胞分离术(GMA)的使用趋势。
在分别为8037例和6153例儿童UC和CD住院病例中,生物制剂的使用显著增加(CD:从46.0%增至53.6%;UC:从15.0%增至33.0%,P<0.0001)。CD患儿中胶囊内镜的使用从6.6%显著增至16.7%(P<0.0001),而TPN的使用从8.4%降至3.0%(P<0.0001)。CD患者的手术率保持在约5%,而UC患者的手术率下降(从3.7%降至1.7%,P=0.002)。CD患儿要素饮食的使用增加(从54.4%增至66.2%,P<0.0001)。UC患者中GMA的使用显著减少(从12.1%降至2.7%,P<0.0001)。
IBD儿童患者生物制剂和胶囊内镜的使用增加,而侵入性更强的治疗方法使用减少。这些趋势表明在日本IBD儿童患者管理中向侵入性更小、更具针对性的治疗策略转变。